Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2022 Jan 7;12(1):220.
doi: 10.1038/s41598-021-04342-0.

Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

Nan Yao #  1 , Wenzai Shi #  2 , Tong Liu  3 , Sarah Tan Siyin  4 , Weiqi Wang  1 , Ning Duan  1 , Guoshuai Xu  1 , Jun Qu  5   6
Affiliations
Comparative Study

Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

Nan Yao et al. Sci Rep. .

Abstract

Male breast cancer (MBC) is rare. Due to limited information, MBC has always been understudied. We conducted a retrospective population-based cohort study using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. The clinical and biological features of female breast cancer (FBC) patients were compared with MBC patients. Cox regression models and competing risks analyses were used to identify risk factors associated with cancer-related survival in MBC and FBC groups. Results showed that MBC patients suffered from higher TNM stages, tumor grades, and a higher percentage of hormone receptor-positive tumors, compared with FBC patients (all p < 0.05). In addition, the breast tumor locations varied a lot between males and females (p < 0.05). FBC patients were associated with superior overall survival than MBC patients. Results from multivariate cox regression and competing risks analyses showed age, race, T, N, M-stages, tumor grades, estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) overexpression were independent prognosis factors in FBC patients (all p < 0.05). MBC patients had similar risk factors to FBC patients, but PR and HER-2 status did not independently influence survival (all p > 0.05). Tumor location was an independent prognostic factor for both gender groups.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow chart of patients’ selection for final analysis.
Figure 2
Figure 2
Breast-cancer-specific survival between the MBC and FBC groups.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138. - DOI - PubMed
    1. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367(9510):595–604. doi: 10.1016/S0140-6736(06)68226-3. - DOI - PubMed
    1. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: A population-based study. Cancer. 2004;101(1):51–57. doi: 10.1002/cncr.20312. - DOI - PubMed
    1. English JC, Middleton C, Patterson JW, Slingluff CL. Cancer of the male breast. Int. J. Dermatol. 2000;39(12):881–886. doi: 10.1046/j.1365-4362.2000.00007.x. - DOI - PubMed

Publication types

MeSH terms